Adial Pharmaceuticals, Inc. Operating Expenses
Adial Pharmaceuticals, Inc. (ADIL) reported Operating Expenses of $52.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $52.02M, a 2664.35% increase year-over-year.
- Adial Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $2.00M, a 11.72% decline year-over-year.
- Adial Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $1.89M, a 2.85% decline year-over-year.
- Adial Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $1.76M, a 20.23% decline year-over-year.
- Adial Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $7.80M, a 5.85% decline from fiscal 2024.
- Adial Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $8.28M, a 20.27% increase from fiscal 2023.
- Adial Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $6.89M, a 36.57% decline from fiscal 2022.
- Adial Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $10.86M, a 43.70% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $52.02M 10-Q · filed 2026-08-14 | $54.03M 10-Q · filed 2026-08-14 | $55.91M derived: sum of 3 quarters · filed 2026-08-14 | $57.68M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-08 | $3.89M derived: sum of 2 quarters · filed 2026-05-08 | $5.65M derived: sum of 3 quarters · filed 2026-05-08 | $7.53M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.65M derived: sum of 2 quarters · filed 2026-03-05 | $5.53M derived: sum of 3 quarters · filed 2026-08-14 | $7.80M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $1.76M 10-Q · filed 2025-11-13 | $3.65M derived: sum of 2 quarters · filed 2026-08-14 | $5.91M 10-Q · filed 2025-11-13 | $7.85M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $1.88M 10-Q · filed 2026-08-14 | $1.88M 10-Q · filed 2025-08-13 | $4.15M 10-Q · filed 2026-08-14 | $4.15M 10-Q · filed 2025-08-13 | $6.09M derived: sum of 3 quarters · filed 2026-08-14 | $8.30M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $2.27M 10-Q · filed 2026-05-08 | $4.21M derived: sum of 2 quarters · filed 2026-05-08 | $6.42M derived: sum of 3 quarters · filed 2026-05-08 | $8.71M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.15M derived: sum of 2 quarters · filed 2026-03-05 | $6.44M derived: sum of 3 quarters · filed 2026-03-05 | $8.28M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $2.21M 10-Q · filed 2025-11-13 | $4.50M derived: sum of 2 quarters · filed 2025-11-13 | $6.34M 10-Q · filed 2025-11-13 | $8.13M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $2.29M 10-Q · filed 2025-08-13 | $4.13M 10-Q · filed 2025-08-13 | $5.92M derived: sum of 3 quarters · filed 2025-08-13 | $7.27M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $1.85M 10-Q · filed 2025-05-14 | $3.63M derived: sum of 2 quarters · filed 2025-05-14 | $4.99M derived: sum of 3 quarters · filed 2025-05-14 | $6.46M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $3.14M derived: sum of 2 quarters · filed 2025-03-04 | $4.62M derived: sum of 3 quarters · filed 2025-03-04 | $6.89M 10-K · filed 2025-03-04 | ||||
| 2023-09-30 | $1.36M 10-Q · filed 2024-11-13 | $2.84M derived: sum of 2 quarters · filed 2024-11-13 | $5.10M 10-Q · filed 2024-11-13 | $8.35M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $1.48M 10-Q · filed 2024-08-13 | $3.75M 10-Q · filed 2024-08-13 | $7.00M derived: sum of 3 quarters · filed 2024-08-13 | $9.55M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $2.92M 10-Q · filed 2023-05-12 | $5.52M derived: sum of 2 quarters · filed 2024-04-01 | $8.07M derived: sum of 3 quarters · filed 2024-04-01 | $11.32M derived: sum of 4 quarters · filed 2024-04-01 | ||||
| 2022-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $5.15M derived: sum of 2 quarters · filed 2024-04-01 | $8.40M derived: sum of 3 quarters · filed 2024-04-01 | $10.86M 10-K · filed 2024-04-01 | $13.32M 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $2.55M 10-Q · filed 2023-11-14 | $3.19M 10-Q · filed 2022-11-14 | $5.80M derived: sum of 2 quarters · filed 2023-11-14 | $8.26M 10-Q · filed 2023-11-14 | $10.08M 10-Q · filed 2022-11-14 | $14.84M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $3.24M 10-Q/A · filed 2023-10-30 | $3.83M 10-Q · filed 2022-08-15 | $5.71M 10-Q/A · filed 2023-10-30 | $6.89M 10-Q · filed 2022-08-15 | $12.28M derived: sum of 3 quarters · filed 2023-10-30 | $16.35M derived: sum of 4 quarters · filed 2023-10-30 | ||
| 2022-03-31 | $3.06M 10-Q · filed 2023-05-12 | $9.04M derived: sum of 2 quarters · filed 2023-05-12 | $13.10M derived: sum of 3 quarters · filed 2023-05-12 | $17.51M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $10.04M derived: sum of 2 quarters · filed 2023-03-30 | $14.45M derived: sum of 3 quarters · filed 2023-03-30 | $19.29M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $4.06M 10-Q · filed 2022-11-14 | $8.47M derived: sum of 2 quarters · filed 2022-11-14 | $13.31M 10-Q · filed 2022-11-14 | $16.78M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $4.40M 10-Q · filed 2022-08-15 | $9.24M 10-Q · filed 2022-08-15 | $12.71M derived: sum of 3 quarters · filed 2022-08-15 | $16.05M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $4.84M 10-Q · filed 2022-05-16 | $8.31M derived: sum of 2 quarters · filed 2022-05-16 | $11.65M derived: sum of 3 quarters · filed 2022-05-16 | $13.47M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $3.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $6.81M derived: sum of 2 quarters · filed 2022-03-28 | $8.63M derived: sum of 3 quarters · filed 2022-03-28 | $10.93M 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | $3.34M 10-Q · filed 2021-11-15 | $5.16M derived: sum of 2 quarters · filed 2021-11-15 | $7.46M 10-Q · filed 2021-11-15 | $9.55M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $1.82M 10-Q · filed 2021-08-12 | $4.12M 10-Q · filed 2021-08-12 | $6.21M derived: sum of 3 quarters · filed 2021-08-12 | $7.96M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $2.30M 10-Q · filed 2021-05-17 | $4.39M derived: sum of 2 quarters · filed 2021-05-17 | $6.14M derived: sum of 3 quarters · filed 2021-05-17 | $8.30M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $3.84M derived: sum of 2 quarters · filed 2021-03-22 | $6.00M derived: sum of 3 quarters · filed 2021-03-22 | $8.24M 10-K · filed 2021-03-22 | ||||
| 2019-09-30 | $1.75M 10-Q · filed 2020-11-13 | $3.90M derived: sum of 2 quarters · filed 2020-11-13 | $6.15M 10-Q · filed 2020-11-13 | $7.24M derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2019-06-30 | $2.16M 10-Q · filed 2020-08-13 | $4.41M 10-Q · filed 2020-08-13 | $5.50M derived: sum of 3 quarters · filed 2020-08-13 | $9.31M derived: sum of 4 quarters · filed 2020-08-13 | ||||
| 2019-03-31 | $2.25M 10-Q · filed 2020-05-14 | $3.34M derived: sum of 2 quarters · filed 2020-05-14 | $7.16M derived: sum of 3 quarters · filed 2020-05-14 | $8.90M derived: sum of 4 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $4.91M derived: sum of 2 quarters · filed 2020-03-20 | $6.65M derived: sum of 3 quarters · filed 2020-03-20 | $6.99M 10-K · filed 2020-03-20 | ||||
| 2018-09-30 | $3.82M 10-Q · filed 2019-11-14 | $5.56M derived: sum of 2 quarters · filed 2019-11-14 | $5.90M 10-Q · filed 2019-11-14 | $6.22M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $1.74M 10-Q · filed 2018-09-10 | $2.08M 10-Q · filed 2019-08-13 | $2.40M derived: sum of 3 quarters · filed 2019-08-13 | $2.67M derived: sum of 4 quarters · filed 2019-08-13 | ||||
| 2018-03-31 | $339.51K 10-Q · filed 2019-05-13 | $661.31K derived: sum of 2 quarters · filed 2019-05-13 | $923.72K derived: sum of 3 quarters · filed 2019-05-13 | $1.17M derived: sum of 4 quarters · filed 2019-05-13 | ||||
| 2017-12-31 | $321.79K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $584.21K derived: sum of 2 quarters · filed 2019-02-19 | $825.70K derived: sum of 3 quarters · filed 2019-02-19 | $995.29K 10-K · filed 2019-02-19 | ||||
| 2017-09-30 | $262.42K 10-Q · filed 2018-11-14 | $503.90K derived: sum of 2 quarters · filed 2018-11-14 | $673.49K 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | $241.49K 10-Q · filed 2018-09-10 | $411.08K 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |